Harvard Bioscience (NASDAQ:HBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Harvard Bioscience (NASDAQ:HBIO) from a hold rating to a buy rating in a research report report published on Monday.

A number of other analysts have also recently weighed in on HBIO. Weiss Ratings restated a “sell (e+)” rating on shares of Harvard Bioscience in a research note on Wednesday, October 8th. Benchmark dropped their price objective on Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating on the stock in a report on Wednesday, September 10th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Harvard Bioscience currently has an average rating of “Hold” and a consensus price target of $2.00.

Harvard Bioscience Stock Down 3.2%

NASDAQ HBIO opened at $0.62 on Monday. Harvard Bioscience has a 52 week low of $0.28 and a 52 week high of $2.40. The firm has a 50 day moving average of $0.48 and a two-hundred day moving average of $0.47. The stock has a market capitalization of $27.63 million, a PE ratio of -0.48 and a beta of 1.60.

Institutional Trading of Harvard Bioscience

Large investors have recently made changes to their positions in the company. Nuveen LLC purchased a new position in shares of Harvard Bioscience during the first quarter worth approximately $79,000. Williams & Novak LLC raised its position in Harvard Bioscience by 37.0% in the 2nd quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 28,800 shares during the last quarter. Deutsche Bank AG boosted its stake in Harvard Bioscience by 221.1% during the 1st quarter. Deutsche Bank AG now owns 75,985 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 52,319 shares during the period. AMH Equity Ltd grew its position in Harvard Bioscience by 3.6% during the 2nd quarter. AMH Equity Ltd now owns 3,508,703 shares of the medical instruments supplier’s stock worth $1,557,000 after purchasing an additional 121,348 shares during the last quarter. Finally, Pasadena Private Wealth LLC grew its position in Harvard Bioscience by 23.2% during the 2nd quarter. Pasadena Private Wealth LLC now owns 243,911 shares of the medical instruments supplier’s stock worth $108,000 after purchasing an additional 45,872 shares during the last quarter. 80.87% of the stock is owned by institutional investors and hedge funds.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.